Precision Psychiatry Challenges Genomics as the Primary Lens for Mental Health Treatment

Precision medicine has long leaned heavily on genomic data as its foundational currency, but a prominent voice in psychiatry is pushing back on that assumption. Amit Etkin, a leading neuroscientist and pioneer in computational psychiatry, argues that brain activity — not genetic variation — represents the more actionable and clinically meaningful signal for advancing personalized mental health treatment. His perspective, published this week in Inside Precision Medicine, carries significant implications for how the genomics industry positions itself within the broader precision medicine ecosystem.

The Case Against Genomics as Psychiatry's North Star

Etkin's core argument centers on the gap between genomic association and clinical utility in psychiatric contexts. While genome-wide association studies have identified thousands of variants linked to conditions like depression, schizophrenia, and bipolar disorder, translating those associations into treatment decisions has proven stubbornly difficult. Psychiatric disorders are polygenic in the extreme, shaped by hundreds or thousands of small-effect variants interacting with environmental and developmental factors in ways that current models cannot reliably resolve at the individual patient level. For genomics professionals, this is a familiar limitation — one that the field has been working to address through polygenic risk scoring and pharmacogenomic stratification — but Etkin contends that brain-based biomarkers derived from EEG and neuroimaging may simply offer a shorter path from measurement to meaningful clinical action.

What Brain Activity Biomarkers Offer Instead

The alternative Etkin champions is rooted in electrophysiological and imaging-derived signatures of brain circuit function. These markers, he argues, are closer mechanistically to the symptoms psychiatrists actually treat and respond more dynamically to therapeutic intervention. This is not an entirely novel claim, but Etkin's work has helped formalize it through rigorous biomarker validation frameworks. Importantly, his position does not dismiss genetics entirely. Pharmacogenomics, which examines how genetic variants influence drug metabolism and receptor sensitivity, retains a credible role. The dispute is really about which data layer should anchor the overarching precision psychiatry framework — and Etkin places his bet firmly on neural circuitry.

Implications for the Genomics Industry

For companies and laboratories operating in the clinical genomics space, this debate is worth watching closely. Psychiatric indications represent one of the largest untapped markets for genomic testing, and any shift in clinical consensus about the primacy of genetic data could reshape reimbursement pathways, test ordering behavior, and partnership strategies. At the same time, Etkin's critique may accelerate productive integration rather than displacement, prompting multi-modal diagnostic approaches that layer pharmacogenomic panels alongside neuroimaging biomarkers.

As precision psychiatry matures, the genomics industry will need to demonstrate clear clinical decision support value — not just biological association — to secure its role at the center of mental health care.